Department of Hematology, Xi'an Central Hospital, Xi'an, Shaanxi, China.
Eur Rev Med Pharmacol Sci. 2018 Sep;22(18):5892-5898. doi: 10.26355/eurrev_201809_15917.
Long non-coding RNA SNHG15 (SNHG15) has been reported to play very important roles in the malignancy behaviors of various tumors, including pancreatic ductal adenocarcinoma (PDAC). However, its clinical significance in PDAC remains largely unclear. The aim of this study was to investigate whether the aberrant expression of SNHG15 can be used as potential prognostic and diagnostic markers of human PDAC.
TaqMan Real Time-PCR was performed to investigate the expression of SNHG15 in PDAC tissues and serum samples. Receiver operator characteristic (ROC) analysis was applied to obtain the diagnostic utility of SNHG15. Association between SNHG15 levels and clinicopathological factors was analyzed. Kaplan-Meier curves and multivariate Cox proportional models were used to study the impact on clinical outcome.
SNHG15 levels were significantly up-regulated in both sera and tumors tissues from PDAC patients. ROC curve analysis revealed that SNHG15 may be a potential biomarker for differentiating PDAC tissues from normal pancreatic tissues, and the plasma levels of SNHG15 may be a potential biomarker for differentiating PDAC patients from healthy controls. Clinicopathologic analysis revealed that high SNHG15 expression was associated with tumor differentiation (p = 0.000), lymph node metastasis (p = 0.001) and tumor stage (p = 0.005). Furthermore, patients with high SNHG15 expression had a shorter overall survival compared with the low SNHG15 expression group (p = 0.003). Also, Cox multivariate analyses confirmed that SNHG15 expression was an independent prognostic factor in PDAC (p < 0.004).
Our study firstly indicated the potential value of SNHG15 as an important biomarker for the diagnosis and prognosis prediction of PDAC.
长链非编码 RNA SNHG15（SNHG15）已被报道在多种肿瘤的恶性行为中发挥非常重要的作用，包括胰腺导管腺癌（PDAC）。然而，其在 PDAC 中的临床意义在很大程度上仍不清楚。本研究旨在探讨 SNHG15 的异常表达是否可以作为人类 PDAC 的潜在预后和诊断标志物。
采用 TaqMan 实时 PCR 检测 PDAC 组织和血清样本中 SNHG15 的表达。应用受试者工作特征（ROC）曲线分析获得 SNHG15 的诊断效用。分析 SNHG15 水平与临床病理因素的相关性。Kaplan-Meier 曲线和多变量 Cox 比例模型用于研究对临床结局的影响。
SNHG15 在 PDAC 患者的血清和肿瘤组织中均显著上调。ROC 曲线分析表明，SNHG15 可能是区分 PDAC 组织与正常胰腺组织的潜在生物标志物，而 SNHG15 的血浆水平可能是区分 PDAC 患者与健康对照者的潜在生物标志物。临床病理分析显示，高 SNHG15 表达与肿瘤分化（p = 0.000）、淋巴结转移（p = 0.001）和肿瘤分期（p = 0.005）相关。此外，高 SNHG15 表达的患者总生存期较 SNHG15 低表达组缩短（p = 0.003）。此外，Cox 多因素分析证实 SNHG15 表达是 PDAC 的独立预后因素（p < 0.004）。
本研究首次表明 SNHG15 作为 PDAC 诊断和预后预测的重要生物标志物具有潜在价值。
